Safety issues in isotretinoin therapy

N. Hanson, S. Leachman

Research output: Contribution to journalReview articlepeer-review

46 Scopus citations


Isotretinoin (Accutane, Roche Laboratories Inc, Nutley, NJ) is an important drug, not only for the treatment of severe acne, but also for other diagnoses and in chemoprevention settings. Because the use of isotretinoin is increasing, it is important for physicians to be aware of the adverse events, toxicities, and management issues related to its use. The most important issue is that of congenital defects, which has resulted in new pregnancy prevention policies and programs implemented by the manufacturer. A relatively new concern is that of depression associated with isotretinoin use, also resulting in new policies placed by the manufacturer and the FDA. The most common adverse effects observed during treatment are mucocutaneous and ocular in nature, but laboratory abnormalities and effects in the nervous, musculoskeletal, gastrointestinal, pulmonary, hematologic, and other systems are also described. Additionally, potential drug interactions, follow-up, and toxicity prevention measures are discussed.

Original languageEnglish (US)
Pages (from-to)166-183
Number of pages18
JournalSeminars in cutaneous medicine and surgery
Issue number3
StatePublished - 2001
Externally publishedYes

ASJC Scopus subject areas

  • Surgery
  • Dermatology


Dive into the research topics of 'Safety issues in isotretinoin therapy'. Together they form a unique fingerprint.

Cite this